Prohost Letter #433
The most common genetic blood disorders are the hemoglobinopathies: sickle cell disease (SCD) and beta-thalassemia. Millions of people around the world are affected by these two
conditions in which genetic defects impact the hemoglobin production.We called the past week “The Hemoglobinopathies’ Week”. Important and impacting news came with promising clinical trials data from two products aimed at treating sickle cell disease. The products are: voxelotor, which belongs to the firm Global Blood Therapeutics (This content is for paid subscribers.